Bespak, a leader in specialized drug delivery solutions, has officially expanded its intranasal portfolio with the launch of the NasaDose Ultra Soft Unit Dose Spray. This innovative device represents a significant leap forward in delivery technology, merging Bespak’s proven NasaDose unit dose architecture with the advanced, proprietary soft mist technology developed by its joint venture partner, Resyca.
The new platform is the first to integrate these two distinct, high-performance systems into a single, cohesive delivery mechanism. By utilizing Resyca’s soft mist technology, the device produces a fine, low-velocity spray. This design is engineered specifically to provide consistent aerosol performance while simultaneously reducing the mechanical stress often placed on fragile drug formulations. Complementing this is Bespak’s signature spring-powered actuation system, which ensures a precise, repeatable dose regardless of the user’s force or speed, effectively minimizing the impact of operator variability.
Industry experts believe the device addresses a critical need for pharmaceutical companies working with sensitive materials. The system can be highly customized to meet unique requirements, including adjustments to spray characteristics, dose volume, and actuation force. Furthermore, it is engineered for precision, allowing for targeted deposition within the nasal cavity—a vital feature for reaching specific areas such as the turbinate and olfactory regions.
“NasaDose Ultra Soft Unit Dose Spray brings together our established NasaDose platform with Resyca’s proprietary soft mist technology, expanding the options available to customers developing the next generation of nasal therapies,” said Chris Hirst, CEO of Bespak. “Combined with our growing formulation and development capabilities, this gives customers a strong platform to progress promising nasal drug products from early development towards clinical and commercial supply.”
The versatility of the platform positions it as a go-to solution for a wide range of therapeutic applications. Beyond traditional small molecules, the device is uniquely suited to handle complex biologics, including proteins and peptides, which can often be compromised or degraded by the shear stress typical of standard aerosolization methods. Consequently, the device shows significant promise for local nasal therapies, vaccines, and prophylactic treatments. Most notably, the system is expected to advance the field of systemic drug delivery, particularly regarding “nose-to-brain” pathways and treatments for the central nervous system (CNS), where targeted, consistent delivery is paramount.
This launch reinforces Bespak’s long-term strategy to provide a comprehensive, end-to-end nasal drug delivery service. By offering a unified pathway—spanning everything from early-stage formulation development and device engineering to clinical supply and full-scale commercial manufacturing—Bespak continues to solidify its role as a key partner for biotech and pharmaceutical firms looking to bring sophisticated nasal treatments to market.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
